We next dosed several KRAS mutant cell line derived xenograft (CDX) and patient‐derived xenograft (PDX) models including NSCLC, CRC, Pancreatic cancer, ovarian cancer, and esophageal cancer with IN10018. Here, KRAS is linked to non-small cell lung carcinoma.